Patents by Inventor Kristine E. Frank

Kristine E. Frank has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL TRICYCLIC COMPOUNDS
    Publication number: 20230082167
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: January 14, 2022
    Publication date: March 16, 2023
    Inventors: Neil WISHART, Maria A. ARGIRIADI, David J. CALDERWOOD, Anna M. Ericsson, Bryan A. FIAMENGO, Kristine E. FRANK, Michael M. FRIEDMAN, Dawn M. GEORGE, Eric R. GOEDKEN, Nathan S. JOSEPHSOHN, Biqin C. LI, Michael J. MORYTKO, Kent D. STEWART, Jeffrey W. VOSS, Grier A. WALLACE, Lu WANG, Kevin R. WOLLER
  • PRIMARY CARBOXAMIDES AS BTK INHIBITORS
    Publication number: 20210179556
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: February 11, 2021
    Publication date: June 17, 2021
    Inventors: Dominique Bonafoux, Heather Michele Davis, Kristine E. Frank, Michael M. Friedman, J. Martin Herold, Michael Z. Hoemann, Raymond Huntley, Augustine Osuma, George Sheppard, Gagandeep Kaur Somal, Jennifer Van Camp, Stacy Anne Van Epps, Anil Vasudevan, Grier Allan Wallace, Lu Wang, Lu Wang, Zhi Wang, Noel S. Wilson, Xiangdong Xu
  • NOVEL TRICYCLIC COMPOUNDS
    Publication number: 20210061813
    Abstract: The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: June 13, 2019
    Publication date: March 4, 2021
    Applicant: AbbVie Inc.
    Inventors: Neil WISHART, Maria A. ARGIRIADI, David J. CALDERWOOD, Anna M. ERICSSON, Bryan A. FIAMENGO, Kristine E. FRANK, Michael M. FRIEDMAN, Dawn M. GEORGE, Eric R. GOEDKEN, Nathan S. JOSEPHSOHN, Biqin C. LI, Michael J. MORYTKO, Kent D. STEWART, Jeffrey W. VOSS, Grier A. WALLACE, Lu WANG, Kevin R. WOLLER
  • INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING
    Publication number: 20200255423
    Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.
    Type: Application
    Filed: October 16, 2019
    Publication date: August 13, 2020
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Ellen Yulin Tsai Chien, Marlon D. Cowart, Kristine E. Frank, Michael M. Friedman, David J. Hardee, J. Martin Herold, Huaqing Liu, Wei Qiu, Marc J. Scanio, Michael R. Schrimpf, Thomas R. Vargo, Stacy A. Van Epps, Matthew P. Webster, Andrew J. Little, Matthew H. Katcher, Theresa A. Dunstan, David A. Schiedler
  • Inhibitors of tyrosine kinase 2 mediated signaling
    Patent number: 10508113
    Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, nad n are as defined herein, pharmaeceutical compositions 2C X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: December 17, 2019
    Assignee: AbbVie Inc.
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Ellen Yulin Tsai Chien, Marlon D. Cowart, Kristine E. Frank, Michael M. Friedman, David J. Hardee, J. Martin Herold, Huaqing Liu, Wei Qiu, Marc J. Scanio, Michael R. Schrimpf, Thomas R. Vargo, Stacy A. Van Epps, Matthew P. Webster, Andrew J. Little, Matthew H. Katcher
  • PRIMARY CARBOXAMIDES AS BTK INHIBITORS
    Publication number: 20190284135
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: May 23, 2019
    Publication date: September 19, 2019
    Inventors: Dominique Bonafoux, Heather Michele Davis, Kristine E. Frank, Michael M. Friedman, J. Martin Herold, Michael Z. Hoemann, Raymond Huntley, Augustine Osuma, George Sheppard, Gagandeep Kaur Somal, Jennifer Van Camp, Stacy Anne Van Epps, Anil Vasudevan, Grier Allan Wallace, Lu Wang, Lu Wang, Zhi Wang, Noel S. Wilson, Xiangdong Xu
  • INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING
    Publication number: 20190276450
    Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.
    Type: Application
    Filed: March 12, 2019
    Publication date: September 12, 2019
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Ellen Yulin Tsai Chien, Marlon D. Cowart, Kristine E. Frank, Michael M. Friedman, David J. Hardee, J. Martin Herold, Huaqing Liu, Wei Qiu, Marc J. Scanio, Michael R. Schrimpf, Thomas R. Vargo, Stacy A. Van Epps, Matthew P. Webster, Andrew J. Little, Matthew H. Katcher
  • HETEROCYCLIC KINASE INHIBITORS
    Publication number: 20190135836
    Abstract: This invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers, and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: December 21, 2018
    Publication date: May 9, 2019
    Inventors: Michael Friedman, Phil Cox, Kristine E. Frank, Michael Z. Hoemann, Augustine Osuma, Noel S. Wilson, Xiangdong Xu, Kevin Cusack, Raymond Huntley, J. Martin Herold
  • Heterocyclic kinase inhibitors
    Patent number: 10280184
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: May 7, 2019
    Assignee: AbbVie Inc.
    Inventors: Michael M. Friedman, Philip Cox, Kristine E. Frank, Michael Z. Hoemann, Augustine Osuma, Noel S. Wilson, Xiangdong Xu, Kevin Cusack, Raymond Huntley, J. Martin Herold
  • Tricyclic modulators of TNF signaling
    Patent number: 10266532
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: April 23, 2019
    Assignee: AbbVie Inc.
    Inventors: Eric C. Breinlinger, Phil B. Cox, Justin D. Dietrich, Kristine E. Frank, Michael M. Friedman, Huan-Qui Li, Kenton L. Longenecker, Augustine T. Osuma, Ann Marie Rowley, Anil Vasudevan, Noel S. Wilson, Jerome Daanen, Stevan Djuric, Amanda W. Dombrowski, Arthur Gomtsyan, Robert Schmidt
  • Substituted cyanoguanidines as oral anti-virals
    Patent number: 10112911
    Abstract: This disclosure relates to: (a) compounds and salts of formula (I), formula (II), formula (III), and formula (IV), that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: October 30, 2018
    Assignee: ABBVIE INC.
    Inventors: Artour Gomtsian, Tatyana Dekhtyar, Kristine E. Frank, Michael M. Friedman, Nathan Josephsohn, M-Akhteruzzaman Molla, Anil Vasudevan, Iok Chan Ng, Mikhail Chafeev
  • NOVEL TRICYCLIC COMPOUNDS
    Publication number: 20180291029
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: November 7, 2017
    Publication date: October 11, 2018
    Applicant: AbbVie Inc.
    Inventors: Neil WISHART, Maria A. Argiriadi, David J. Calderwood, Anna M. Ericsson, Bryan R. Fiamengo, Kristine E. Frank, Michael M. Friedman, Dawn M. George, Eric R. Goedken, Nathan S. Josephsohn, Biqin C. Li, Michael J. Morytko, Kent D. Stewart, Jeffrey W. Voss, Grier A. Wallace, Lu Wang, Kevin R. Woller
  • TRICYCLIC MODULATORS OF TNF SIGNALING
    Publication number: 20180179198
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Application
    Filed: December 1, 2017
    Publication date: June 28, 2018
    Inventors: Eric C. Breinlinger, Phil B. Cox, Justin D. Dietrich, Kristine E. Frank, Michael M. Friedman, Huan-Qui Li, Kenton L. Longenecker, Augustine T. Osuma, Ann Marie Rowley, Anil Vasudevan, Noel S. Wilson
  • Tricyclic modulators of TNF signaling
    Patent number: 9856253
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: January 2, 2018
    Assignee: AbbVie, Inc.
    Inventors: Eric C. Breinlinger, Phil B. Cox, Justin Dietrich, Kristine E. Frank, Michael M. Friedman, Huan-Qui Li, Kenton Longenecker, Augustine Osuma, Ann Marie Rowley, Anil Vasudevan, Noel Wilson
  • PRIMARY CARBOXAMIDES AS BTK INHIBITORS
    Publication number: 20170174624
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: January 5, 2017
    Publication date: June 22, 2017
    Applicant: AbbVie Inc.
    Inventors: Dominique Bonafoux, Heather M. Davis, Kristine E. Frank, Michael M. Friedman, J. Martin Herold, Michael Z. Hoemann, Raymond Huntley, Augustine Osuma, George Sheppard, Gagandeep K. Somal, Jennifer Van Camp, Stacy A. Van Epps, Anil Vasudevan, Grier A. Wallace, Lu Wang, Lu Wang, Zhi Wang, Noel S. Wilson, Xiangdong Xu
  • HETEROCYCLIC KINASE INHIBITORS
    Publication number: 20170114077
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: April 16, 2015
    Publication date: April 27, 2017
    Inventors: Michael M. FRIDEMAN, Philip COX, Kristine E. FRANK, Michael Z. HOEMANN, Augustine OSUMA, Noel S. WILSON, Xiangdong XU, Kevin CUSACK, Raymond HUNTLEY, J. Martin HEROLD
  • Primary carboxamides as BTK inhibitors
    Patent number: 9567339
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: February 14, 2017
    Assignee: AbbVie Inc.
    Inventors: Dominique Bonafoux, Heather M. Davis, Kristine E. Frank, Michael M. Friedman, J. Martin Herold, Michael Z. Hoemann, Raymond Huntley, Augustine Osuma, George Sheppard, Gagandeep K. Somal, Jennifer Van Camp, Stacy A. Van Epps, Anil Vasudevan, Grier A. Wallace, Lu Wang, Lu Wang, Zhi Wang, Noel S. Wilson, Xiangdong Xu
  • NOVEL TRICYCLIC COMPOUNDS
    Publication number: 20160326181
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: May 12, 2016
    Publication date: November 10, 2016
    Applicant: AbbVie Inc.
    Inventors: Neil Wishart, Maria A. Argiriadi, David J. Calderwood, Anna M. Ericsson, Bryan R. Fiamengo, Kristine E. Frank, Michael M. Friedman, Dawn M. George, Eric R. Goedken, Nathan S. Josephsohn, Biqin C. Li, Michael J. Morytko, Kent D. Stewart, Jeffrey W. Voss, Grier A. Wallace, Lu Wang, Kevin R. Woller
  • TRICYCLIC MODULATORS OF TNF SIGNALING
    Publication number: 20160304517
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Inventors: Eric C. Breinlinger, Phil B. Cox, Jerome Daanen, Justin Dietrich, Stevan Djuric, Amanda W. Dombrowski, Kristine E. Frank, Michael M. Friedman, Arthur Gomtsyan, Huan-Qui Li, Kenton Longenecker, Augustine Osuma, Ann Marie Rowley, Robert Schmidt, Anil Vasudevan, Noel Wilson
  • Tricyclic compounds
    Patent number: RE47221
    Abstract: The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: February 5, 2019
    Assignee: AbbVie Inc.
    Inventors: Neil Wishart, Kristine E. Frank, Michael Friedman, Dawn M. George, Kent D. Stewart, Grier A. Wallace